Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Cash from Operations (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Cash from Operations for 17 consecutive years, with 10600000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 60.61% to 10600000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 1800000.0, a 120.69% increase, with the full-year FY2025 number at 1800000.0, up 120.69% from a year prior.
  • Cash from Operations was 10600000.0 for Q4 2025 at Myriad Genetics, down from 21100000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 71800000.0 in Q1 2021 to a low of 54700000.0 in Q4 2023.
  • A 5-year average of 10275000.0 and a median of 8400000.0 in 2021 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: tumbled 1029.55% in 2022, then surged 2914.29% in 2025.
  • Myriad Genetics' Cash from Operations stood at 9500000.0 in 2021, then rose by 23.16% to 7300000.0 in 2022, then tumbled by 649.32% to 54700000.0 in 2023, then soared by 112.07% to 6600000.0 in 2024, then skyrocketed by 60.61% to 10600000.0 in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Cash from Operations are 10600000.0 (Q4 2025), 21100000.0 (Q3 2025), and 13600000.0 (Q2 2025).